TRCT
AGL icon

Tower Research Capital (TRC)’s Agilon Health AGL Stock Holding History

Tower Research Capital (TRC)’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17K Buy
2,152
+1,092
+103% +$17.7K ﹤0.01% 3593
2025
Q4 		$18.3K Sell
1,060
-318
-23% -$6.17K ﹤0.01% 3163
2025
Q3 		$35.5K Sell
1,378
-105
-7% -$3.97K ﹤0.01% 2790
2025
Q2 		$85.3K Buy
1,483
+1,011
+214% +$81.1K ﹤0.01% 2512
2025
Q1 		$51.1K Buy
472
+49
+12% +$4.26K ﹤0.01% 2217
2024
Q4 		$20.1K Buy
423
+44
+12% +$2.66K ﹤0.01% 3178
2024
Q3 		$37.3K Buy
379
+125
+49% +$16.1K ﹤0.01% 2885
2024
Q2 		$41.5K Buy
254
+178
+234% +$25.4K ﹤0.01% 3234
2024
Q1 		$11.6K Sell
76
-326
-81% -$54.2K ﹤0.01% 3555
2023
Q4 		$126K Sell
402
-544
-58% -$197K ﹤0.01% 2463
2023
Q3 		$420K Buy
946
+653
+223% +$295K 0.01% 969
2023
Q2 		$127K Sell
293
-263
-47% -$148K ﹤0.01% 1890
2023
Q1 		$330K Sell
556
-271
-33% -$152K 0.01% 1083
2022
Q4 		$334K Buy
827
+605
+273% +$284K 0.01% 949
2022
Q3 		$130K Buy
222
+94
+73% +$56.3K ﹤0.01% 2319
2022
Q2 		$70K Sell
128
-64
-33% -$32.4K ﹤0.01% 2571
2022
Q1 		$122K Buy
192
+171
+814% +$88.1K ﹤0.01% 2060
2021
Q4 		$14K Sell
21
-1,132
-98% -$689K ﹤0.01% 4048
2021
Q3 		$756K Buy
1,153
+1,044
+958% +$892K 0.02% 704
2021
Q2 		$110K Buy
+109
New +$95.5K ﹤0.01% 2348

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Tower Research Capital (TRC)'s AGL Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Agilon Health (AGL) stake by 103% in Q1 2026, buying an estimated $17.7K and bringing the position to 2,152 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #3593.

Tower Research Capital (TRC) first reported a position in AGL in Q2 2021 and has held it in 20 quarters since. The position peaked at $756K in Q3 2021. 97 funds tracked by Wall St. Rank hold AGL as of Q1 2026.

  • Tower Research Capital (TRC) held 2,152 shares of Agilon Health worth $17K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,092 Agilon Health shares in Q1 2026, an estimated $17.7K.
  • Agilon Health made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3593 holding.
  • Tower Research Capital (TRC) first reported a position in Agilon Health in Q2 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Agilon Health position peaked at $756K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Agilon Health as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.